Anixa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AB</div>
ANIX -- USA Stock  

USD 2.49  0.04  1.58%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Anixa Biosciences against current market trends. As we have suggested previously, Anixa Biosciences is beginning its slide as investors shift to be more bearish due to the increased sector volatility. Anixa Biosciences moves indifferently to market moves. The returns on investing in Anixa Biosciences and the market returns of the last few months appear uncorrelated. Strong basic indicators of the company may suggest signs of short-term price drift for investors. Anixa Biosciences is scheduled to announce its earnings tomorrow. The next earnings report is expected on the 14th of January 2021. The stock experiences a sell-off trend.
Published over three weeks ago
View all stories for Anixa Biosciences | View All Stories
Will Anixa Biosciences (NASDAQ:ANIX) continue to slide in October?
This firm's average rating is Strong Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Anixa Biosciences market sentiment investors' perception of the future value of Anixa. Let us look at a few aspects of Anixa technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Anixa Biosciences. In general, we focus on analyzing Anixa Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anixa Biosciences's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Anixa Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Anixa Biosciences, we also check how macroeconomic factors affect Anixa Biosciences price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Anixa Stands against Peers?

Analyzing Anixa Biosciences competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Anixa Biosciences across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Anixa Biosciences Competition Details

How Anixa utilizes its cash?

To perform a cash flow analysis of Anixa Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Anixa Biosciences is receiving and how much cash it distributes out in a given period. The Anixa Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Anixa Biosciences Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Net Cash Flow from Operations of (4.27 Million) in 2019

Purchase by Lewis Titterton of 40000 shares of Anixa Biosciences

Legal trades by Anixa Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Anixa insider trading alert for perchase of common stock by Lewis Titterton, the corporate stakeholder, on 14th of September 2020. This event was filed by Anixa Biosciences Inc with SEC on 2020-09-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Anixa Biosciences Indicators

The company has a beta of -0.1223. Let's try to break down what Anixa's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Anixa Biosciences will likely underperform. The beta indicator helps investors understand whether Anixa Biosciences moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Anixa deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Net Loss for the year was (9.46 M) with profit before overhead, payroll, taxes, and interest of 83.75 K.

Is Anixa showing appearance of lower volatility?

Potential upside is down to 9.55. It may suggest a possible volatility slide. Anixa Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Anixa Biosciences independently to ensure intended market timing strategies are aligned with expectations about Anixa Biosciences volatility.

Our Final Perspective on Anixa Biosciences

When is the right time to buy or sell Anixa Biosciences? Buying stocks such as Anixa Biosciences isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. On the whole, as of the 4th of September 2020, we believe that at this point, Anixa Biosciences is very risky with average chance of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our up-to-date 30 days buy vs. sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Anixa Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com